Novo Nordisk (NVO) on Tuesday reported mixed financials for 2025 and initiated its 2026 outlook, indicating a contraction in its business amid upcoming patent cliffs for its blockbuster GLP-1 therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results